Huntington's disease is an inherited neurodegenerative disorder. It belongs to the polyQ accumulation disease with mutant Huntingtin protein. The mutant Huntingtin has expended CAG triplet repeats which make it easily accumulate. However, the exact mechanism causing Huntington's disease pathophysiology is unknown. Here, I
We also find out that many TH17 related transcription factors are up-regulated in caudate nucleus of Huntington's disease patients. (Table 9 ) CEBPD and CEBPB are transcription factors of TH17 immunity, and the two transcription factors are up-regulated in caudate nucleus of Huntington's patients. AP-1, a TH17 dominant transcription factor, is also up-regulated including Jun and Fos in caudate nucleus of Huntington's disease. STAT3, NFkBIA, and IKBKB are key transcription factors for driving TH17 immunity, and they all are up-regulated. STAT4, a key transcription factor for traditional TH1 immunity, is down-regulated in caudate nucleus of Huntington's disease patients.
Up-regulation of TH17 related effector molecules in caudate nucleus of Huntington's disease patients
In caudate nucleus of Huntington's disease patients, many TH17 related effector molecules are up-regulated including complements, Fc receptors, and S100 binding proteins. (Table 10 ) Most of the complement components are up-regulated, and complements are major TH17 effector molecules. S100 binding proteins are key chemoattractants for neutrophils, major TH17 effector cells. Fc receptors including CD64 are also up-regulated, and these phagocyte related Fc receptors may enhance neutrophil and macrophage ADCC machinery. The above evidences all suggest that TH17 immunity is up-regulated in Huntington's disease.
Up-regulation of apoptosis molecules in caudate nucleus of Huntington's disease patients In caudate nucleus of Huntington's patients, many apoptosis molecules are up-regulated. (Table 11 ) These molecules can be up-regulated by TH17 cytokines such as IL-1 and TNF alpha. Fas inhibitory molecules and caspase 8 which is up-regulated by TNF alpha are up-regulated in caudate nucleus of Huntington's disease.
Up-regulation of TH17 related cytokines in peripheral leukocytes of Huntington's disease patients
In this microarray analysis, we find out that many TH17 related cytokines are up-regulated in peripheral leukocytes of Huntington's disease patients. (Table 12) Among all of them, IL-1 and IL-8 are mostly highly up-regulated. These two cytokines are key effector cytokines in TH17 immunity. IL-1 plays an essential role in TH17 helper cell differentiation. Thrombospondin, an activator of TGF beta, is also up-regulated in peripheral leukocytes of Huntington's patients. TGF beta is another key cytokine to drive TH17 differentiation. IRAK2 and IL-1 member 7 are also up-regulated in peripheral leukocytes of Huntington's disease. In addition, many TH17 cytokine receptors are up-regulated including tumor necrosis factor receptor 10b, IL-17 receptor E, and IL-22 receptor alpha1.
Up-regulation of TH17 related transcription factors in peripheral leukocytes of Huntington's disease patients In this analysis, I find that many TH17 driven transcription factors are up-regulated in peripheral leukocytes of Huntington's disease patients. (Table 13 ) NFKBIA, NFKBIZ, and NFKB2 are up-regulated in Huntington's disease. NFKBIA is the inhibitor of NFKB1.
NFKB1 deficiency can cause hyperproduction of TH17 helper cells. In addition, NFKBIA and NFKBIZ are essential in TH17 immunological pathway development.
NFKB2 is important in B cell homeostasis and proliferation. IKKB, the inhibitor of NFKB2, can suppress TH17 immunity related granulocytosis. Thus, NFKB2 also plays an important role in TH17 immunity. Fos antigen, forming AP-1 transcription factor, is also up-regulated after Huntington's disease. AP-1 is another key transcription factor in TH17 immunity. Besides, up-regulated SMAD4 is the downstream molecule of TGF beta signaling, an important cytokine for TH17 initiation.
Up-regulation of Th17 related effector molecules in peripheral leukocytes of Huntington's disease patients In this study, I also find out that many TH17 related effector molecule up-regulation in Huntington's disease patients. (Table 14) First of all, complement related genes are up-regulated including complement 8 gamma, decay accelerating factor, and CD46 complement regulatory protein. Second, defensin beta, PGE receptor, mannosidase lysozyme, and IgA Fc receptor are up-regulated in leukocytes of Huntington's patients.
Third, chemokine such as CXCL2, CCL17, and CCL22 are up-regulated. Even CCL17 and CCL22 are not belonged to TH17 immunity, the highest up-regulated CXCL2 is the chemoattractant for TH17 effector neutrophils. Finally, many caspase genes are up-regulated including casapse 2, caspase 8, and caspase 10. These caspases are downstream molecules of TH17 cytokine TNF alpha and IL-1. All the above evidences show that TH17 immunity is dominant in Huntington's disease.
Discussion
Huntington's disease is inherited neurodegenerative disorder. Involuntary chorea is the chief symptom & sign. It is an autosomal dominant disease which is related to the Huntingtin mutation. Huntington's disease is also a Trinucleotide Repeat Disorder that has multiple CAG repeats (coding glutamine) in the exon area. Then, the mutant Huntingtin can be translated into protein with polyglutamine tract (polyQ). The penetrance of Huntington's disease is related to the copy number of the CAG repeats.
If the CAG repeats are greater than 36, Huntington's disease is very likely to happen.
If the CAG repeats are greater than 40, there is a full penetrance to cause Huntington's disease. The onset of Huntington's disease is usually at 35-44 years-old.
Even we know Huntingtin is the key player of Huntington's disease, we still don't understand the exact pathogenesis of Huntington's disease.
Huntingtin is mainly expressed in brain and testis. It is highly expressed in basal ganglia, especially striatum. The disease progression of Huntington's disease is related to the damage of striatum. Caudate nucleus is the major subcomponent of striatum. After the destruction of striatum, Huntington's patients will develop involuntary chorea. We know the mutant Huntingtin can be accumulated in the neurons of striatum. It can be in the cytosol or be linked to plasma membrane. CAG codes glutamine. We know the polyglutamine tract can cause Huntingtin protein to be insoluble and aggregated. In addition, polyglutamine can enhance Huntingtin to insert into plasma membrane lipid bilayer. In a paper, Huntingtin can interact with brain neuron membrane. (Suopanki, Gotz et al. 2006) The physiological function of Huntingtin is related to neurogenesis, and the polyQ tract of mutant Huntingtin doesn't interfere with its normal function. It is also unlikely a sole mutant protein can cause neuron death. If mutant Huntingtin can cause neuron apoptosis, why can't mutant Huntingtin induce neurodegeneration from early childhood or infancy?
However, we don't know why the polyglutamine (polyQ) tail of Huntingtin will cause Huntington's disease. Here, I also propose an autoimmune mechanism for this neurodegenerative disorder. We know the increased CAG triplets can cause disease, but we still don't know why CAG repeats can cause disease. Inflammation or autoimmunity can link the gap between increased DNA CAG triplets and neurodegeneration. During childhood or juvenile period, there should be Huntingtin specific Treg cells to suppress autoimmune reaction against the mutant Huntingtin.
When the patients enter the adulthood with thymus atrophy, the Huntingtin specific Treg may be lost. In addition, the accumulated insoluble membrane-associated mutant Huntingtin can trigger host immune response. Another detrimental TH17 autoimmunity happens.
Although there is ubiquitin-proteasome system impairment associated with accumulated mutant Huntingtin, there are still molecular chaperons including heat shock protein up-regulation in Huntington's disease. (Bence, Sampat et al. 2001) There are down-regulations of ubiquitin and proteasome genes during Huntington's disease. Polyglutamine accumulation can suppress proteasomes. (Verhoef, Lindsten et al. 2002) We can see the differential regulation of heat shock proteins in caudate nucleus in Huntington's disease. Molecular chaperons such as heat shock proteins can be up-regulated due to the accumulation of cytosolic proteins, especially Huntingtin. It is worth noting that several heat shock protein 70 genes are up-regulated in Huntington's disease. In a R6/2 animal model, overexpression of heat shock protein doesn't change the progression of Huntington's disease. It means that heat shock protein up-regulation is not a protective but a contributing factor for the disease. (Hansson, Nylandsted et al. 2003) In addition, Toll-like receptor 5 and CD14 are also up-regulated in Huntington's disease. HSP70 can activate CD14 to induce TH17 cytokines such as IL-1, IL-6, and TNFα. (Freidin, Bennett et al. 1992 It is noted that there is reflective elevation of cortisol in Huntington's disease patients. It implies that there is certain regulatory response to suppress the overt autoimmunity in Huntington's disease patients. In rat models, immunosuppressants cyclosporine A or FK506 can suppress the symptoms and signs of Huntington's disorder. (Kumar, Kalonia et al. 2010 ) Several studies also showed that minocycline, an immunosuppressant to suppress CD4 T cell, macrophage, and IL-6, can be used to treat Huntington's disease, Amyotrophic Lateral Sclerosis, and another TH17 autoimmune disorder: Rheumatoid arthritis. (Chen, Ona et al. 2000; Zanjani, Sabetkasaei et al. 2006; Szeto, Pomerantz et al. 2011) In an Italian research, dexamethasone can improve the symptoms and signs of Huntington's disease. (Nuti, Maremmani et al. 1991; Bonuccelli, Nuti et al. 1992 ) I sincerely hope this paper can provide a new view for preventing and treating the detrimental Huntington's disease. 
